Financial Scaling of Personalized Precision (n=1) mRNA Vaccine Immunotherapies for People Living With Cancer
Our Vision
To deliver a financially scalable business investment model for hospitals, clinics and professional investors, for local delivery of personalized precision (n=1) mRNA cancer immunotherapies for People Living With Cancer in the US, the UK and the EU, in cooperation with leading hospitals and oncologists and strategic industrial partners.
Cancer immunotherapy with personalized precision (n=1) neoantigen targeting is an important new tool for oncologists to treat patients, particularly in combination with gold standard techniques including surgery, radiation and chemotherapy.
Artificial Intelligence (AI) is a transformative new technology for neoantigen discovery and personalized DIGITAL HEALTH services for patients and their doctors.
Every Cancer is Unique. Every Cancer is Personal.
Cancer is a tragic disease which causes unfathomable pain, misery and death.
Oncology represents 25% of the $1.5 trillion global pharmaceutical market.
Cancer will impact up to 1 in 2 people within their lifetime, severely affecting most families.
Personalized Precision (n=1) Immunotherapy is a Powerful New Treatment Option for Oncologists and People Living with Cancer.
“We are thrilled to work with our Strategic Partners and Technology & Service Providers in cooperation with Leading Cancer Hospitals and Oncologists. Our engagement with Financial Advisor Oyster Venture Partners marks an important milestone for Normax Biomed. Their deep expertise in the healthcare sector and network with the professional investment community will be invaluable as we work to scale our Normax Educated Antigen Receptor Therapy (EARTh)™ immunotherapy production capabilities for People Living with Cancer. Our flagship strategic locations in development in Belgium, United Kingdom, California, Luxembourg and Switzerland will enable Normax to leverage the expertise of leading researchers and clinicians, further accelerating the development and delivery of personalized mRNA cancer vaccines for cancer patients at leading cancer hospitals. Together, we can make a real difference in each personal fight against cancer, with each patient’s oncologist.”
Benefits of Immunotherapy
Immunotherapy offers potential medical benefits for People Living With Cancer, including:
- Targeted Attack: Immunotherapy focuses on targeting specific cancer cells, leaving healthy cells unharmed. This minimizes side effects compared to traditional chemotherapy and radiation.
- Long-lasting Response: Some immunotherapy treatments can lead to long-term remission or even cure, especially when used in combination with other treatments. This is due to the immune system’s ability to “remember” and target cancer cells even after treatment is stopped.
- Improved Quality of Life: Immunotherapy can improve quality of life by reducing side effects and allowing patients to maintain their daily activities with less disruption. This is especially important for those with chronic cancers, as it allows for longer-term survival with a better quality of life.
- Potential for Multiple Treatments: Immunotherapy can be used for various types of cancer, including melanoma, lung cancer, bladder cancer, and many others. The field is continuously evolving, with new immunotherapy treatments being developed for different cancers.
- Combination Therapy: Immunotherapy can be combined with other treatments like chemotherapy, radiation therapy, and surgery to achieve synergistic effects, improving treatment outcomes.
- Increased Survival Rates: In some cases, immunotherapy has been shown to significantly increase survival rates compared to traditional therapies. This is particularly true for certain types of cancers where traditional treatments have limited effectiveness.
- Immune System Boost: Immunotherapy can help strengthen the overall immune system, making it more robust against infections and other diseases.
- Reduced Risk of Recurrence: Immunotherapy can help prevent the recurrence of cancer, especially in patients who have achieved complete remission.
- Minimally Invasive: Some immunotherapy treatments, like checkpoint inhibitors, are administered through intravenous infusions, which are minimally invasive compared to surgery or radiation therapy.
- Potential for Personalized Treatment: Immunotherapy treatments are increasingly being tailored to individual patients based on their specific tumor and immune system characteristics, allowing for more personalized care and improved outcomes.
It’s important to remember that immunotherapy may not be recommended for every patient.
The effectiveness of immunotherapy can vary depending on the individual, the type of cancer, and other factors. It’s mandatory and essential to discuss the potential risks and benefits with a healthcare professional to determine if immunotherapy is the right treatment option for each individual patient.
“With an extremely experienced team in strategic cooperation with leading Industrial Partners and leading Cancer Hospitals and Oncologists, Normax Biomed (NRMX) is developing a transformative automated Good Manufacturing Practices (GMP) technology for personalized drug development in combination with advanced artificial intelligence processing of patient data with leading AI partners, for rapid delivery of mRNA vaccine immunotherapy for each individual cancer patient. We are excited to support NRMX in its mission and Oyster Venture Partners is committed to work with NRMX investors to bring this transformative product to market with the potential to transform the lives of People Living with Cancer with immunotherapy treatments in the United States, the United Kingdom and the European Union.”
Normax Strategic Partners & Collaborators + Science, Technology & Service Providers + Leading Cancer Hospitals & Oncologists
